Ondansetron (Sanis Health) Product Monograph

RECENT MAJOR LABEL CHANGES

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES ............................................................................................ 2

TABLE OF CONTENTS .............................................................................................................. 2

PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4

1 INDICATIONS .................................................................................................................. 4

1.1 Pediatrics (≤18 years of age) ........................................................................................ 4

1.2 Geriatrics (>65 years of age) ........................................................................................ 4

2 CONTRAINDICATIONS ..................................................................................................... 4

4 DOSAGE AND ADMINISTRATION ..................................................................................... 5

4.1 Dosing Considerations .................................................................................................. 5

4.2 Recommended Dose and Dosage Adjustment ............................................................ 5

4.4 Administration .............................................................................................................. 8

5 OVERDOSAGE ................................................................................................................. 8

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ..................................... 8

7 WARNINGS AND PRECAUTIONS ...................................................................................... 9

7.1 Special Populations .................................................................................................... 11

7.1.1 Pregnant Women ....................................................................................................... 11

7.1.2 Breast-feeding ............................................................................................................ 11

7.1.3 Pediatrics .................................................................................................................... 12

7.1.4 Geriatrics .................................................................................................................... 12

8 ADVERSE REACTIONS ..................................................................................................... 12

8.2 Clinical Trial Adverse Reactions .................................................................................. 12

8.5 Post-Market Adverse Reactions ................................................................................. 13

9 DRUG INTERACTIONS .................................................................................................... 14

9.1 Serious Drug Interactions ........................................................................................... 14 9.2 Drug Interactions Overview ....................................................................................... 14

9.4 Drug-Drug Interactions ............................................................................................... 15

9.5 Drug-Food Interactions .............................................................................................. 16

9.6 Drug-Herb Interactions .............................................................................................. 16

9.7 Drug-Laboratory Test Interactions ............................................................................. 16

10 CLINICAL PHARMACOLOGY ............................................................................................ 16

10.1 Mechanism of Action ................................................................................................. 16

10.2 Pharmacodynamics .................................................................................................... 17

10.3 Pharmacokinetics ....................................................................................................... 19

11 STORAGE, STABILITY AND DISPOSAL .............................................................................. 21

12 SPECIAL HANDLING INSTRUCTIONS ................................................................................ 21

PART II: SCIENTIFIC INFORMATION ........................................................................................ 22

13 PHARMACEUTICAL INFORMATION ................................................................................. 22

14 CLINICAL TRIALS............................................................................................................. 23

14.1 Trial Design and Study Demographics ........................................................................ 23

14.2 Study Results .............................................................................................................. 23

14.3 Comparative Bioavailability Studies ........................................................................... 24

15 MICROBIOLOGY ............................................................................................................. 25

16 NON-CLINICAL TOXICOLOGY .......................................................................................... 25

17 SUPPORTING PRODUCT MONOGRAPHS ......................................................................... 30

PATIENT MEDICATION INFORMATION ................................................................................... 31

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

Adults (18-64 years of age)

ONDANSETRON is indicated for:

• the prevention of nausea and vomiting associated with emetogenic chemotherapy, including high dose cisplatin, and radiotherapy.
• the prevention and treatment of post-operative nausea and vomiting.

1.1 Pediatrics (≤18 years of age)

Post-Chemotherapy Induced Nausea and Vomiting

• Pediatrics (4-12 years of age): Ondansetron was effective and well tolerated when given to children 4-12 years of age.
• Pediatrics (<4 years of age): ONDANSETRON is not indicated for the treatment of children less than 4 years old.

Post-Radiotherapy Induced Nausea and Vomiting

ONDANSETRON is not indicated for this use in any pediatric population.

Post-Operative Nausea and Vomiting

ONDANSETRON is not indicated for this use in any pediatric population.

1.2 Geriatrics (>65 years of age)

Post-Chemotherapy and Radiotherapy Induced Nausea and Vomiting

Efficacy and tolerance of ondansetron was similar to that observed in younger adults. See 4.2 Recommended Dose and Dosage Adjustment, Chemotherapy induced Nausea and Vomiting, Use in Elderly; 7 WARNINGS AND PRECAUTIONS, Cardiovascular; 7.1.4 Geriatrics; 10.3 Pharmacokinetics, Geriatrics.

Post-Operative Nausea and Vomiting

Clinical experience in the use of ondansetron in the prevention and treatment of post-operative nausea and vomiting is limited; ONDANSETRON is not indicated for this use in the geriatric population.

2 CONTRAINDICATIONS

• ONDANSETRON is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
• The concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

Visually inspect IV solutions and discard if particulate matter or discolouration are observed. See 4.4 Administration.

ONDANSETRON clearance is reduced in patients with moderate or severe hepatic impairment. Their total daily dose should not exceed 8 mg, which may be given as a single intravenous or oral dose. See 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic.

ONDANSETRON have important cardiac side-effects dose-dependent QTc prolongation, coronary artery spasm, myocardial ischemia, and sequelae). These effects are reported more often with intravenous administration, and are expected to be greater with a faster rate of infusion. See 7 WARNINGS AND PRECAUTIONS, Cardiovascular, QTc Interval Prolongation; and Myocardial Ischemia and Coronary Artery Spasm; 9.4 Drug-Drug Interactions, QTc-Prolonging Drugs; 10.2 Pharmacodynamics, Electrocardiography.

Though ONDANSETRON efficacy and tolerance were similar for elderly compared to younger adults in chemotherapy clinical trials, exposure-response modelling predicted a greater effect on QTcF in patients ≥75 years of age compared to young adults. See 10.3 Pharmacokinetics, Geriatrics.

Dosing considerations that reduce cardiac risks:

• Use the minimum effective dose.
• Use oral formulations if possible (lower Cmax).

The efficacy of ONDANSETRON in highly emetogenic chemotherapy may be enhanced by the addition of a single intravenous dose of dexamethasone sodium phosphate 20 mg administered prior to chemotherapy.

The efficacy of twice daily dosage regimens for the treatment of post-chemotherapy emesis has been established only in adult patients receiving less emetogenic chemotherapy. The appropriateness of twice versus three times daily dosage regimens for other patient groups should be based on an assessment of the needs and responsiveness of the individual patient.

4.2 Recommended Dose and Dosage Adjustment

Highly Emetogenic Chemotherapy Induced Nausea and Vomiting

Caution: To reduce cardiac risks, carefully follow the dosing guidelines under 4.1 Dosing Considerations.

• Use in Adults (only)

  • Initial IV dose, diluted (see 4.4 Administration), infused over 15 minutes, given 30 minutes before chemotherapy:

    • usually 8 mg.
    • maximum 16 mg.

  • Post-chemotherapy:

    • 4 hours and 8 hours after the initial dose: 8 mg IV, infused over 15 minutes.
    • After the first 24 hours: 8 mg orally every 8 hours, for up to 5 days.

Less Emetogenic Chemotherapy Induced Nausea and Vomiting

Caution: To reduce cardiac risks, carefully follow the dosing guidelines under 4.1 Dosing Considerations.

• Use in Adults:

  • Initial dose:

    • 8 mg orally, given 1-2 hours before chemotherapy.

      OR

    • 8 mg IV, diluted (see 4.4 Administration), infused over 15 minutes, given 30 minutes before chemotherapy.
  • After chemotherapy: doses of 8 mg orally, twice daily, for up to 5 days.

• Use in Children 4-12 years of age

  • Initial dose: 3 to 5 mg/m2 IV, infused over 15 minutes, at least 30 minutes before chemotherapy.
  • After chemotherapy: 4 mg orally, every 8 hours.

• Use in Children <4 years of age

  ONDANSETRON is not indicated for this use in this pediatric population.

• Use in Elderly (<=65 years of age):

  See 4.4 Administration; 10.3 Pharmacokinetics, Geriatrics.

Elderly (65-74 years of age):

• Initial IV dose: 8 mg or 16* mg, diluted, infused over 15 minutes.

• May be followed by two IV doses of 8 mg, diluted, infused over 15 minutes, at least 4 hours apart.

  * When the initial dose is 16 mg, there is a predicted increase of the risk for a slight QTcF interval prolongation above 10 ms (from baseline) for about 10 min. ECG monitoring may be considered.

Elderly (>=75 years of age):

• Initial IV dose: maximum 8 mg, diluted, infused over 15 minutes.

• May be followed by two IV doses** of 8 mg, diluted, infused over 15 minutes, at least 4 hours apart.

  ** For the third dose, there is a predicted increase of the risk for a slight QTcF interval prolongation above 10 ms (from baseline) for about 10 min. ECG monitoring may be considered.

Radiotherapy Induced Nausea and Vomiting

Caution: To reduce cardiac risks, carefully follow the dosing guidelines under 4.1 Dosing Considerations.

• Use in Adults:

  • Initial dose: 8 mg orally, given 1 to 2 hours before radiotherapy.
  • After radiotherapy: 8 mg orally, given every 8 hours, for up to 5 days after a course of treatment.

• Use in Children (<18 years of age):

  ONDANSETRON is not indicated for this use in the pediatric population.

• Use in Elderly (<=65 years of age):

  See Use in Adults, and 4.1 Dosing Considerations; 10.3 Pharmacokinetics, Geriatrics.

Post-Operative Nausea and Vomiting

• Use in Adults:

  • For prevention:

    • One hour prior to anaesthesia: 16 mg orally.

      OR

    • At induction of anaesthesia: 4 mg IV, undiluted, infused - preferably over 2-5 minutes, and not less than 30 seconds.

  • For established post-operative nausea and vomiting:

    • A single dose of 4 mg IV, infused - preferably over 2-5 minutes, and not less than 30 seconds.

• Use in Children (<18 years of age):

  ONDANSETRON is not indicated for this use in the pediatric population.

• Use in Elderly (<=65 years of age):

  ONDANSETRON is not indicated for this use in the elderly.

4.4 Administration

Administration of Tablets

ONDANSETRON tablets should be swallowed whole, with a liquid.

5 OVERDOSAGE

At present there is little information concerning overdosage with ondansetron. Individual doses of 84 mg and 145 mg and total daily doses as large as 252 mg have been administered with only mild side effects. There is no specific antidote for ondansetron, therefore, in cases of suspected overdosage, symptomatic and supportive therapy should be given as appropriate.

The use of Ipecac to treat overdosage with ondansetron is not recommended as patients are unlikely to respond due to the antiemetic action of ondansetron itself.

“Sudden blindness” (amaurosis) of 2 to 3 minutes duration plus severe constipation occurred in one patient that was administered 72 mg of ondansetron intravenously as a single dose. Hypotension (and faintness) occurred in another patient that took 48 mg of oral ondansetron. Following infusion of 32 mg over only a 4-minute period, a vasovagal episode with transient second degree heart block was observed. Neuromuscular abnormalities, autonomic instability, somnolence, and a brief generalized tonic-clonic seizure (which resolved after a dose of benzodiazepine) were observed in a 12-months’ old infant who ingested seven or eight 8-mg ondansetron tablets (approximately forty times the recommended 0.1-0.15 mg/kg dose for a paediatric patient). In all instances, the events resolved completely.

Ondansetron prolongs QT interval in a dose-dependent fashion (see 10.2 Pharmacodynamics). ECG monitoring is recommended in cases of overdose.

Cases consistent with serotonin syndrome have been reported in young children following oral overdose.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Tablets:

ONDANSETRON 4 mg tablets: Each tablet contains: medicinal ingredient: 4 mg of ondansetron base, in the form of ondansetron hydrochloride dihydrate. Non-Medicinal ingredients: cellulose microcrystalline, lactose monohydrate, starch (pregelatinised), magnesium stearate, hypromellose, titanium dioxide, glycerol triacetate, ferric oxide yellow.

ONDANSETRON 4 mg tablets are yellow, film-coated, oval shaped tablets. Available in bottle of 100.

ONDANSETRON 8 mg tablets: Each tablet contains: Medicinal ingredient: 8 mg of ondansetron base, in the form of ondansetron hydrochloride dihydrate. Non-Medicinal ingredients: cellulose microcrystalline, lactose monohydrate, starch (pregelatinised), magnesium stearate, hypromellose, titanium dioxide, glycerol triacetate, ferric oxide yellow.

ONDANSETRON 8 mg tablets are yellow, film-coated, oval shaped tablets. Available in bottle of 100.

7 WARNINGS AND PRECAUTIONS

General

ONDANSETRON is not effective in preventing motion-induced nausea and vomiting.

Cardiovascular

QTc Interval Prolongation: Ondansetron prolongs the QT interval (see 10 CLINICAL PHARMACOLOGY, Electrocardiography). The magnitude of QTc prolongation will depend on the peak serum ondansetron concentration (C_max), which is substantially determined by the route of administration, the dose and the infusion rate of intravenous ondansetron. In addition, post-marketing cases of torsade de pointes have been reported in patients using ondansetron. Torsade de Pointes is a polymorphic ventricular tachyarrhythmia. Generally, the risk of torsade de pointes increases with the magnitude of QTc prolongation produced by the drug. Torsade de pointes may be asymptomatic or experienced by the patient as dizziness, palpitations, syncope, or seizures. If sustained, torsade de pointes can progress to ventricular fibrillation and sudden cardiac death.

Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to either QT prolongation or electrolyte abnormalities (see 9 DRUG INTERACTIONS). Hypokalaemia, hypocalcaemia and hypomagnesemia should be corrected prior to ondansetron administration.

Additional risk factors for torsade de pointes in the general population include, but are not limited to, the following:

• female gender;
• age 65 years or older;
• baseline prolongation of the QT/QTc interval;
• presence of genetic variants affecting cardiac ion channels or regulatory proteins;
• family history of sudden cardiac death at <50 years;
• cardiac disease (e.g., myocardial ischemia or infarction, left ventricular hypertrophy, cardiomyopathy, conduction system disease);
• history of arrhythmias (especially ventricular arrhythmias, atrial fibrillation, or recent conversion from atrial fibrillation);
• bradycardia (<50 beats per minute);
• acute neurological events (e.g., intracranial or subarachnoid haemorrhage, stroke, intracranial trauma);
• nutritional deficits (e.g., eating disorders, extreme diets);
• diabetes mellitus;
• autonomic neuropathy.

Myocardial Ischemia and Coronary Artery Spasm: Ondansetron can cause coronary artery vasospasm and myocardial ischemia which may lead to myocardial infarction. In some cases, the symptoms appeared immediately after IV infusion, or shortly after oral administration, including after low doses in patients without significant known pre-existing cardiovascular disease or other risk factors. Caution is advised during and after ondandestron administration, and close monitoring is recommended in patients with known or suspected ischemic or vasospastic coronary artery disease or other significant underlying cardiovascular disease.

Driving and Operating Machinery

In psychomotor testing ondansetron does not impair performance nor cause sedation.

Gastrointestinal

As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration.

Hepatic/Biliary/Pancreatic

Abnormal liver function test results have been reported, as well as liver failure in clinical trial cancer patients. See 8.2 Clinical Trial Adverse Reactions, Hepatic/Biliary/Pancreatic; and 8.5 Post-Market Adverse Reactions.

Immune

Cross-reactive hypersensitivity has been reported between different 5-HT3 antagonists. Patients who have experienced hypersensitivity reactions to one 5-HT3 antagonist have experienced more severe reactions upon being challenged with another drug of the same class. The use of a different 5-HT3 receptor antagonist is not recommended as a replacement in cases in which a patient has experienced even a mild hypersensitivity type reaction to another 5-HT3 antagonist.

Neurologic

Serotonin syndrome/Neuroleptic Malignant Syndrome: Cases of life-threatening serotonin syndrome or neuroleptic malignant syndrome-like events have been reported with 5-HT3 receptor antagonist antiemetics, including ondansetron, when given in combination with other serotonergic and/or neuroleptic drugs. Serotonin syndrome symptoms may include mental status changes (e.g. agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea). As these syndromes may result in potentially life-threatening conditions, treatment should be discontinued if such events occur and supportive symptomatic treatment should be initiated. If concomitant treatment of ONDANSETRON with a drug affecting the serotonergic neurotransmitter system is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see 9 DRUG INTERACTIONS).

Reproductive Health: Female and Male Potential

Pregnancy status should be verified for females of reproductive potential prior to starting the treatment with ONDANSETRON.

Females of reproductive potential should be advised that it is possible that ONDANSETRON can cause harm to the developing foetus. Sexually active females of reproductive potential should use effective contraception (methods that result in less than 1% pregnancy rates) when using ONDANSETRON and for two days after stopping treatment with ONDANSETRON.

7.1 Special Populations

7.1.1 Pregnant Women

The use of ondansetron in pregnancy is not recommended. Ondansetron use during early pregnancy has been associated with a small increase in orofacial malformations. Despite some limitations in methodology, several human epidemiological studies noted an increase in orofacial clefts in infants of women administered ondansetron during the first trimester of pregnancy. Regarding cardiac malformations, the epidemiological studies showed conflicting results.

Ondansetron is not teratogenic in animals (see 16 NON-CLINICAL TOXICOLOGY, Reproductive and Developmental Toxicology).

7.1.2 Breast-feeding

Ondansetron is excreted in the milk of lactating rats. It is not known if it is excreted in human milk, however, nursing is not recommended during treatment with ondansetron.

7.1.3 Pediatrics

Insufficient information is available to provide dosage recommendations for children 3 years of age or younger.

7.1.4 Geriatrics

Early Phase I studies in healthy elderly volunteers showed a slight age-related decrease in clearance, and an increase in half-life of ondansetron. A greater effect on QTcF is predicted in patients ≥75 years of age compared to young adults, based on exposure-response modelling. See 10.3 Pharmacokinetics, Geriatrics.

8 ADVERSE REACTIONS

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Ondansetron has been administered to over 2500 patients worldwide in controlled clinical trials and has been well tolerated.

The most frequent adverse events reported in controlled clinical trials were headache (11%) and constipation (4%). Other adverse events include sensations of flushing or warmth (< 1%).

Cardiovascular: There have been rare reports of tachycardia, angina (chest pain), bradycardia, hypotension, syncope and electrocardiographic alterations.

Central Nervous System: There have been rare reports of seizures. Movement disorders and dyskinesia have been reported in two large clinical trials of ondansetron at a rate of 0.1-0.3%.

Dermatological: Rash has occurred in approximately 1% of patients receiving ondansetron.

Eye Disorder: Rare cases of transient visual disturbances (e.g. blurred vision) have been reported during or shortly after intravenous administration of ondansetron, particularly at rates equal to or greater than 30 mg in 15 minutes.

Hepatic/ Biliary / Pancreatic

There were transient increases of SGOT and SGPT of over twice the upper limit of normal in approximately 5% of patients. These increases did not appear to be related to dose or duration of therapy. There have been reports of liver failure and death in patients with cancer receiving concurrent medications including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. The etiology of the liver failure is unclear.

Hypersensitivity: Rare cases of immediate hypersensitivity reactions sometimes severe, including anaphylaxis, bronchospasm, urticaria and angioedema have been reported.

Local Reactions: Pain, redness and burning at the site of injection have been reported.

Metabolic: There have been rare reports of hypokalaemia.

Other: There have been reports of abdominal pain, weakness and xerostomia.

8.5 Post-Market Adverse Reactions

Over 250 million patient treatment days of ondansetron have been supplied since the launch of the product worldwide. The following events have been spontaneously reported during post-approval use of ondansetron, although the link to ondansetron cannot always be clearly established.

The adverse event profiles in children and adolescents were comparable to that seen in adults.

Immune Disorders: Rare cases of hypersensitivity reactions, sometimes severe (e.g., laryngeal oedema, stridor, laryngospasm and cardiopulmonary arrest) have also been reported.

Cardiovascular Disorders: There have been rare reports (<0.01%) of myocardial infarction, myocardial ischemia, angina, chest pain with or without ST segment depression, arrhythmias (including ventricular or supraventricular tachycardia, premature ventricular contractions, and atrial fibrillation), electrocardiographic alterations (including second degree heart block), palpitations and syncope.

Rarely and predominantly with intravenous ondansetron, transient ECG changes including QTc interval prolongation, Torsade de Pointes, ventricular fibrillation, coronary artery spasm, cardiac arrest, and sudden death have been reported (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular).

Eye Disorder: There have been very rare cases of transient blindness following ondansetron treatment, generally within the recommended dosing range and predominantly during intravenous administration.

The majority of blindness cases reported resolved within 20 minutes. Although most patients had received chemotherapeutic agents, including cisplatin a few cases of transient blindness occurred following ondansetron administration for the treatment of postoperative nausea or vomiting and in the absence of cisplatin treatment. Some cases of transient blindness were reported as cortical in origin.

Hepatic/Biliary/Pancreatic: Occasional asymptomatic increases in liver function tests have been reported.

Nervous System Disorders: Transient episodes of dizziness (< 0.1%) have been reported predominantly during or upon completion of IV infusion of ondansetron.

Uncommon reports (< 1%) suggestive of extrapyramidal reactions including oculogyric crisis/dystonic reactions (e.g. oro-facial dyskinesia, opisthotonos, tremor, etc.), movement disorders and dyskinesia have been reported without definitive evidence of persistent clinical sequelae.

Serotonin syndrome and neuroleptic malignant syndrome-like events have been reported with 5-HT3 receptor antagonist antiemetics, including ondansetron, when given in combination with other serotonergic and/or neuroleptic drugs (see 7 WARNINGS AND PRECAUTIONS, Neurologic).

Respiratory, Thoracic and Mediastinal Disorders: There have also been rare reports of hiccups.

Skin and Subcutaneous Tissue Disorders: Very rare reports have been received for bullous skin and mucosal reactions, including fatal cases. These reports include toxic skin eruptions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, and have occurred in patients taking other medications that can be associated with bullous skin and mucosal reactions.

9 DRUG INTERACTIONS

9.1 Serious Drug Interactions

Serious Drug Interactions (see 9.4 Drug-Drug Interactions)

• Apomorphine (see 2 CONTRAINDICATIONS)
• QTc-Prolonging drugs
• Serotonergic agents

9.2 Drug Interactions Overview

Ondansetron is extensively metabolised by multiple hepatic cytochrome P450 enzymes (predominately CYP3A4, CYP2D6 and CYP1A2), and clearance is reduced in hepatic insufficiency (see 10.3 Pharmacokinetics, Hepatic Insufficiency). CYP 3A4 inducers can increase ondansetron clearance (see 9.4. Drug-Drug Interactions, CYP 3A4 Inducers).

Ondansetron does not itself appear to induce or inhibit the cytochrome P450 drug-metabolizing enzyme system of the liver.

9.4 Drug-Drug Interactions

CYP 3A4 inducers: Despite the multiplicity of metabolic enzymes capable of metabolising ondansetron, which might be expected to compensate for an increase or decrease in enzyme activity, patients treated with inducers of CYP3A4 (i.e. phenytoin, carbamazepine, and rifampicin) demonstrated an increase in oral clearance of ondansetron and a decrease in ondansetron blood concentrations.

In a pharmacokinetic study of 16 epileptic patients maintained chronically on carbamazepine or phenytoin (CYP 3A4 inducers), reduction in AUC, Cmax and T½ of ondansetron was observed. This resulted in a significant increase in clearance. However, on the basis of the inter-subject variability in the available data, no dosage adjustment can be recommended.

CYP 2D6 inhibitors: No effect in ondansetron clearance secondary to enzyme inhibition has been identified to date.

QTc-Prolonging Drugs: The concomitant use of ONDANSETRON with another QTc prolonging drug should be carefully considered to determine that the therapeutic benefit outweighs the potential risk. Drugs that have been associated with QTc interval prolongation and/or torsade de pointes include, but are not limited to, the examples in the following list. Chemical/pharmacological classes are listed if some, although not necessarily all, class members have been implicated in QTc prolongation and/or torsade de pointes:

• Class IA antiarrhythmics (e.g., quinidine, procainamide, disopyramide);
• Class III antiarrhythmics (e.g., amiodarone, sotalol, ibutilide, dronedarone);
• Class 1C antiarrhythmics (e.g., flecainide, propafenone);
• antiemetics (e.g., dolasetron, palonosetron, granisetron droperidol, chlorpromazine, prochlorperazine);
• tyrosine kinase inhibitors (e.g., vandetanib, sunitinib, nilotinib, lapatinib);
• antipsychotics (e.g., chlorpromazine, pimozide, haloperidol, ziprasidone);
• antidepressants (e.g., citalopram, fluoxetine, venlafaxine, tricyclic/tetracyclic antidepressants e.g., amitriptyline, imipramine, maprotiline);
• opioids (e.g., methadone);
• domperidone
• macrolide antibiotics and analogues (e.g., erythromycin, clarithromycin, telithromycin, tacrolimus);
• quinolone antibiotics (e.g., moxifloxacin, levofloxacin, ciprofloxacin);
• antimalarials (e.g., quinine, chloroquine);
• azole antifungals (e.g., ketoconazole, fluconazole, voriconazole);
• histone deacetylase inhibitors (e.g., vorinostat);
• beta-2 adrenoceptor agonists (e.g., salmeterol, formoterol).

Drugs that Cause Electrolyte Abnormalities: The use of ondansetron with drugs that can disrupt electrolyte levels should be avoided. Such drugs include, but are not limited to, the following:

• loop, thiazide, and related diuretics;
• laxatives and enemas;
• amphotericin B;
• high dose corticosteroids.

The above lists of potentially interacting drugs are not comprehensive. Current information sources should be consulted for newly approved drugs that prolong the QTc interval or cause electrolyte disturbances, as well as for older drugs for which these effects have recently been established.

Tramadol: Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.

Apomorphine: Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated (see 2 CONTRAINDICATIONS).

Serotonergic Drugs : As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may occur with 5-HT3 receptor antagonist antiemetic treatment when given in combination with other agents that may affect the serotonergic neurotransmitter system [including triptans, SSRIs, SNRIs, lithium, sibutramine, fentanyl and its analogues, dextromethorphan, tramadol, tapentadol, meperidine, methadone and pertazocine or St. John’s Wort (Hypericum perforatum)] and with drugs which impair metabolism of serotonin (such as MAOIs, including linezolid (an antibiotic which is a reversible non-selective MAOI) and methylene blue) (see 7 WARNINGS AND PRECAUTIONS, Neurologic).

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with food have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with food have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Ondansetron is a selective antagonist of the serotonin receptor subtype, 5-HT3. Its precise mode of action in the control of chemotherapy induced nausea and vomiting is not known.

Cytotoxic chemotherapy and radiotherapy are associated with the release of serotonin (5-HT) from enterochromaffin cells of the small intestine, presumably initiating a vomiting reflex through stimulation of 5-HT3 receptors located on vagal afferents. Ondansetron may block the initiation of this reflex. Activation of vagal afferents may also cause a central release of serotonin from the chemoreceptor trigger zone of the area postrema, located on the floor of the fourth ventricle. Thus, the antiemetic effect of ondansetron is probably due to the selective antagonism of 5-HT3 receptors on neurons located in either the peripheral or central nervous systems, or both.

The mechanisms of ondansetron’s antiemetic action in postoperative nausea and vomiting are not known.

10.2 Pharmacodynamics

Serotonin receptors of the 5-HT3 type are present both peripherally and on vagal nerve terminals. Ondansetron probably acts by preventing activation of these receptors or receptors located in other regions of the central nervous system. Both the peripheral and central nervous systems appear to be involved since both abdominal vagotomy and microinjection of ondansetron and other 5-HT3 antagonists directly into the area postrema eliminate cisplatin-induced emesis, while 5-HT1-like (methiothepin maleate) and 5-HT2 (ketanserin) antagonists have no effect.

Ondansetron is highly selective for 5-HT3 receptors and shows negligible binding to other receptors such as 5-HT1-like, 5-HT2, α1 and α2 adrenoceptors, β1 and β2 adrenoceptors, D1 and D2 muscarinic, nicotinic, GABAA, H1 and H2 receptors.

The pharmacological specificity of ondansetron may explain the observed lack of extrapyramidal side effects often seen following similar therapy with metoclopramide, which preferentially binds to dopamine receptors of the D2 subtype.

In vivo pharmacodynamic studies have investigated the effects of ondansetron on gastric emptying, small bowel transit time and oesophageal motility.

Both oral (16 mg tid) and intravenous (5-10 mg) doses of ondansetron failed to produce a significant effect on gastric emptying in both healthy volunteers and in patients suffering from delayed gastric emptying. However, in one study intravenous doses of 8 mg did increase gastric emptying in over half the volunteers tested.

Intravenous infusion of either 1 mg or 5 mg ondansetron tended to increase small bowel transit times and single intravenous doses of 10 mg ondansetron have been reported to decrease sphincter pressure in the lower oesophagus in some subjects.

Electrocardiography

The effect of ondansetron on the QTc interval was evaluated in a double blind, randomized, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women. Ondansetron was tested at single doses of 8 mg and 32 mg infused intravenously over 15 minutes. At the highest tested dose of 32 mg, prolongation of the Fridericia-corrected QTc interval (QT/RR0.33=QTcF) was observed from 15 min to 4 h after the start of the 15 min infusion, with a maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction of 19.6 (21.5) msec at 20 min.

At the lower tested dose of 8 mg, QTc prolongation was observed from 15 min to 1 h after the start of the 15 minute infusion, with a maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction of 5.8 (7.8) msec at 15 min. The magnitude of QTc prolongation with ondansetron is expected to be greater if the infusion rate is faster than 15 minutes. The 32 mg intravenous dose of ondansetron must not be administered.

No treatment-related effects on the QRS duration or the PR interval were observed at either the 8 or 32 mg dose.

LS Mean Difference (90% CI) in QTcF Interval Between Treatment and Placebo Over Time

An ECG assessment study has not been performed for orally administered Ondansetron. On the basis of pharmacokinetic-pharmacodynamic modelling, an 8 mg oral dose of ondansetron is predicted to cause a mean QTcF increase of 0.7 ms (90% CI -2.1, 3.3) at steady-state, assuming a mean maximal plasma concentration of 24.7 ng/mL (95% CI 21.1, 29.0).

The magnitude of QTc prolongation at the recommended 5 mg/m2 dose in paediatrics has not been studied, but pharmacokinetic-pharmacodynamic modelling predicts a mean increase of 6.6 ms (90% CI 2.8, 10.7) at maximal plasma concentrations.

10.3 Pharmacokinetics

Absorption

• Oral administration

Pharmacokinetic studies in human volunteers showed peak plasma levels of 20-30 ng/mL at around 1½ hours after an 8 mg oral dose of ondansetron. Repeat dosing of an 8 mg tablet every 8 hours for 6 days increased the peak plasma value to 40 ng/mL.

• Intravenous administration

Pharmacokinetic studies in human volunteers: An 8 mg infusion of ondansetron resulted in peak plasma levels of 80-100 ng/mL. A continuous intravenous infusion of 1 mg/hour after the initial 8 mg loading dose of ondansetron maintained plasma levels over 30 ng/mL during the following 24-hour period.

Mean Plasma Concentration-Time Curve for Ondansetron 8 mg and 32 mg doses

Linear Scale

Semi-logarithmic Scale

Distribution

The absolute bioavailability of ondansetron in humans was approximately 60% and the plasma protein binding was approximately 73%.

See also 16 NON-CLINICAL TOXICOLOGY, Non-clinical pharmacokinetics.

Metabolism

In vitro metabolism studies have shown that ondansetron is a substrate for human hepatic cytochrome P₄₅₀ enzymes, including CYP1A2, CYP2D6 and CYP3A4. In terms of overall ondansetron turnover, CYP3A4 played the predominant role. Because of the multiplicity of metabolic enzymes capable of metabolising ondansetron, it is likely that inhibition or loss of one enzyme (e.g. CYP2D6 enzyme deficiency) will be compensated by others and may result in little change in overall rates of ondansetron clearance. CYP 3A4 inducers can increase clearance (see 9.4 Drug-Drug Interactions, CYP 3A4 inducers).

Elimination

Following extensive metabolism of an orally or intravenously administered dose, ondansetron is excreted in the urine and faeces. In humans, less than 10% of the dose is excreted unchanged in the urine. The major urinary metabolites are glucuronide conjugates (45%), sulphate conjugates (20%) and hydroxylation products (10%).

The half-life of ondansetron after either an 8 mg oral dose or intravenous dose was approximately 3-4 hours and may be extended to 6-8 hours in the elderly.

Special Populations and Conditions

• Geriatrics

Early Phase I studies in healthy elderly volunteers showed a slight age-related decrease in clearance, and an increase in half-life of ondansetron. However, wide inter-subject variability resulted in considerable overlap in pharmacokinetic parameters between young (< 65 years of age) and elderly subjects (≥ 65 years of age) and there were no overall differences in safety or efficacy observed between young and elderly cancer patients enrolled in CINV clinical trials. (See 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment, Use in Elderly).

Based on more recent ondansetron plasma concentrations and exposure-response modelling, a greater effect on QTcF is predicted in patients ≥75 years of age compared to young adults. Specific dosing information is provided for patients over 65 years of age and over 75 years of age for intravenous dosing. (See 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment, Use in Elderly).

• Genetic Polymorphism

CYP 2D6: The elimination half-life and plasma levels of a single 8 mg intravenous dose of ondansetron did not differ between subjects classified as poor and extensive metabolisers of sparteine and debrisoquine (CYP 2D6 substrates). No alteration of daily dosage or frequency of ondansetron dosing is recommended for patients known to be CYP 2D6 poor metabolisers.

• Hepatic Insufficiency

The clearance of an 8 mg intravenous dose of ONDANSETRON was significantly reduced and the serum half-life significantly prolonged in subjects with severe impairment of hepatic function. In patients with moderate or severe impairment of hepatic function, reductions in dosage are therefore recommended and a total daily dose of 8 mg should not be exceeded. This may be given as a single intravenous or oral dose.

There is no experience in patients who are clinically jaundiced.

• Renal Insufficiency

No alteration of daily dosage, frequency of dosing, or route of administration is required in patients with impaired renal function.

11 STORAGE, STABILITY AND DISPOSAL

Tablets:

ONDANSETRON tablets should be stored at room temperature between 15ºC and 30ºC and protected from light.

12 SPECIAL HANDLING INSTRUCTIONS

Not applicable.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Ondansetron hydrochloride dihydrate

Chemical name: 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-

4H-carbazol-4-one hydrochloride dihydrate

Molecular formula C18H19N3O∙HCl∙2H2O

Molecular mass: 365.86 g/mol

Structural formula:

Physicochemical properties:

Physical description: White to off white powder.

Physical form: Polymorphism: No report on polymorphism has been cited in the literature with regard to ondansetron hydrochloride. Furthermore, efforts made by firm’s Research & Development to assess the potential for polymorphism occurrence in ondansetron hydrochloride resulted consistently in the same crystal structure.

Solubilities: Sparingly soluble in water and in alcohol, soluble in methanol, slightly soluble in methylene chloride. As per USP: sparingly soluble in water and alcohol, soluble in methanol, slightly soluble in isopropyl alcohol and dichloromethane; very slightly soluble in acetone, in chloroform and in ethyl acetate. The melting point of ondansetron hydrochloride dihydrate is about 177° C.

The distribution coefficient between n-octanol and water is pH dependent: log D = 2.2 at a pH of 10.6

log D = 0.6 at a pH of 5.95

pH value: 4.6 -5.0

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

The clinical trial data on which the original indication was authorized is not available.

14.2 Study Results

Clinical trial results showing the number and percentage of patients exhibiting a complete response to ondansetron (0 emetic episodes) are shown in the tables below for both postoperative and chemotherapy induced emesis.

*Results are from an initial study using a different dosing regimen.

*The majority of patients included in the prevention and treatment of postoperative nausea and vomiting studies using ondansetron hydrochloride have been adult women receiving balanced anaesthesia for gynaecological surgery.

*The majority of patients included in the prevention and treatment of postoperative nausea and vomiting studies using ondansetron hydrochloride have been adult women receiving balanced anaesthesia for gynaecological surgery.

*results from a study of adult male and female patients receiving single high dose radiotherapy (800 to 1,000 cGy) over an anterior or posterior field size of ≥ 80 cm2 to the abdomen.

*Patients received the first dose of ondansetron hydrochloride 8 mg tablets or metoclopramide (10 mg) 1-2 hours before radiotherapy. If radiotherapy was given in the morning, 2 additional doses of study treatment were given (1 tablet late afternoon and 1 tablet before bedtime). If radiotherapy was given in the afternoon, patients took only 1 further tablet that day before bedtime. Patients continued oral medication on a 3 times a day basis for 3-5 days.

14.3 Comparative Bioavailability Studies

Please find below the results of the open, randomized, blind, 2 periods, 2-way crossover, bioequivalence study of ondansetron hydrochloride dihydrate (equivalent to 8 mg ondansetron) film-coated tablets (Sanis Health Inc.) and Zofran® 8 mg film-coated tablets (GlaxoSmithKline Inc.) administered as a single oral dose of 8 mg in 18 healthy adult male volunteers under fasting conditions.

Summary Table of Comparative Bioavailability Data for a Single-Dose Fasting Study of Ondansetron Hydrochloride (1 x 8 mg) Tablets

* ONDANSETRON 8 mg tablet manufactured for Sanis Health Inc.

† Zofran® 8 mg Tablets (GSK, Canada.)

§ Expressed as the arithmetic mean (CV%) only.

15 MICROBIOLOGY

Not applicable.

16 NON-CLINICAL TOXICOLOGY

Non-clinical pharmacodynamics

Ferret model: The ferret provides an excellent model for demonstrating the antiemetic action of drugs. Emesis can be induced by antineoplastic drugs or whole body irradiation. Behavioural changes associated with these treatments are noted in these animals and may also provide a parallel for the human experience of nausea.

CINV: The antiemetic action of ondansetron has been evaluated in both male and female ferrets given cisplatin (9-10 mg/kg), cyclophosphamide (200 mg/kg) or irradiation (2 and 8 Gy, 250 kV). Intravenous doses of ondansetron (0.1-1 mg/kg) abolished cisplatin-induced emesis for up to 2 hours. In cyclophosphamide-induced emesis, subcutaneous doses of 0.5 mg/kg ondansetron completely eliminated vomiting, significantly reduced retching and delayed the onset of these responses.

RINV: The radiation-induced emesis, 0.5 mg/kg ondansetron alone completely and rapidly eliminated retching and vomiting.

Dexamethasone: The antiemetic effects of ondansetron (0.1 mg/kg) in combination with dexamethasone (2-5 mg/kg) were potentiated in ferrets with cyclophosphamide-induced emesis, compared with ondansetron alone. Ondansetron with dexamethasone produced a significant reduction in retching (65%) and vomiting (72%).

Gastric emptying: Among its secondary effects, ondansetron has also been shown to cause a dose-dependent increase in the rate of gastric emptying in the guinea pig, which is significant at doses of 0.01-0.1 mg/kg. As gastric stasis is frequently associated with nausea, stimulation of gastric motility may be a beneficial action of ondansetron. In the cat, dog and monkey, ondansetron has little effect on heart rate, blood pressure or ECG at intravenous doses up to 3 mg/kg.

QT-prolongation: A study in cloned human cardiac ion channels has shown ondansetron has the potential to affect cardiac repolarisation via blockade of HERG potassium channels at clinically relevant concentrations. Dose-dependent QT prolongation has been observed in a thorough QT study in human volunteers (see 10.2 Pharmacodynamics, Electrocardiography).

Non-clinical pharmacokinetics: In mice, rats, rabbits and dogs dosed at 1 mg/kg orally and/or intravenously, the plasma half-life of ondansetron was less than 1 hour, but the half-lives of its metabolites were significantly longer. Peak plasma concentrations of ondansetron in rats and dogs ranged from

351 to 419 ng/mL for the IV dose and 8 to 15 ng/mL for the oral dose. Plasma levels were linear over a 30 fold dose range. In repeat dose studies there was no apparent accumulation of ondansetron.

Ondansetron is almost completely absorbed in animals, and is rapidly metabolized by N-demethylation and hydroxylation of the indole ring, followed by conjugation with glucuronic acid and sulphate. There is significant first-pass metabolism after oral doses.

Ondansetron and its metabolites are rapidly and widely distributed in tissues, reaching higher levels than the corresponding plasma levels. In the rat and dog, ondansetron binds reversibly to tissues containing melanin and elastin. In rats and man, plasma protein binding is about 73%, while it is slightly lower in the dog (60%). Ondansetron and its metabolites cross the blood-brain barrier to only a slight extent.

General Toxicology:

• Acute Toxicity

Single doses of ondansetron up to the LD50 in mice and in rats were generally well tolerated. Reactions, including tremor and convulsive behaviour, occurred only at near lethal levels.

Table 6

All deaths resulted from the acute effects of treatment, the observed clinical signs being consistent with the central nervous system effects associated with behavioural depression. These effects were not associated with any apparent histopathological changes in the brain. No target organ toxicity was identified.

• Long term Toxicity

Table 7 - Subacute Toxicity Studies:

Maximum daily dose levels in rats were found to be higher when doses were gradually increased. Identical doses were rapidly lethal to rats not previously exposed to ondansetron. Post-dosing reactions, in both rats and dogs, included ataxia, exophthalmia, mydriasis, tremor and respiratory changes. Increases in liver enzymes (SGPT and SGOT) were noted at high dose levels. Dogs dosed at 6.75 mg/kg/day intravenously exhibited vein irritancy in the form of constriction and thickening, creating resistance to needle penetration. The changes were noted after seven days treatment but were reversed by decreasing the dose concentration.

Table 8 - Chronic Toxicity

Carcinogenicity

There was no evidence of a tumourigenic effect of ondansetron in any tissue.

Mutagenicity

No evidence of mutagenicity was observed in microbial mutagen tests using mutant strains of Salmonella typhimurium, Escherichia coli or Saccharomyces cerevisiae, with or without a rat-liver post-mitochondrial metabolizing system.

There was also no evidence of damage to genetic material noted in in vitro V-79 mammalian cell mutation studies, in vitro chromosome aberration tests using human peripheral lymphocytes, or in vivo chromosome aberration assays in mouse bone marrow.

Reproductive and Developmental Toxicology:

Ondansetron was not teratogenic in rats and rabbits at dosages up to the maximum non-convulsive level, (rat: 15 mg/kg/day, rabbit: 30 mg/kg/day; the maternal dose was approximately 6 and 24 times the maximum recommended human oral dose of 24 mg/day, respectively, based on body surface area). No adverse effects on pregnancy or foetal and post-natal development were detected in rats and no foetal abnormalities were observed in rabbits after oral administration of ondansetron.

A slight maternal toxicity was observed at the highest dose level in intravenous organogenesis (4.0 mg/kg/day) studies in the rabbit. Effects included maternal body weight loss and increased incidence of early foetal death. In a rat fertility study, there was a dose-related decrease in the proportion of surviving pups of the F2 generation; however, the significance of this is unclear.

Administration of ondansetron to pregnant rats and rabbits, indicated there was foetal exposure to low levels of ondansetron and its metabolites. Ondansetron is retained in the foetal eye presumably bound to melanin. In rats, the transfer of ondansetron and its metabolites into breast milk was extensive. The concentration of unchanged ondansetron in breast milk was higher than in corresponding plasma samples.

Daily administration of ondansetron at dosages up to 15 mg/kg/day to pregnant rats (a maternal dose of approximately 6 times the maximum recommended human oral dose of 24 mg/day, based on body surface area) from day 17 of pregnancy to litter day 22 had no effects on pregnancy of the parental generation or on post-natal development and mating of the F1 generation. Foetal development of the F2 generation was comparable to controls; however, the number of implantations and viable foetuses was reduced in the highest dosage group when compared with controls.

17 SUPPORTING PRODUCT MONOGRAPHS

^PrZofran® (Tablets, Oral Solution and Injection) and ^PrZofran® ODT (Oral Disintegrating Tablets), Submission control: 252778, Product Monograph, Novartis Pharmaceuticals Canada Inc., November 9, 2021